NEW YORK, Sept. 20, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Asthma Therapeutics - Pipeline Assessment and Market Forecasts to 2018

http://www.reportlinker.com/p0617089/Asthma-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Asthma Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, "Asthma Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global Asthma Therapeutics market. The report identifies the key trends shaping and driving the global Asthma Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Asthma Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Asthma Therapeutics market. Its scope includes -

- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Asthma Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.

- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.

- Analysis of the current and future competition in the seven key countries Asthma Therapeutics market.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Asthma Therapeutics market.

- Analysis of key recent licensing and partnership agreements in Asthma Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global Asthma Therapeutics market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Asthma Therapeutics market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global Asthma Therapeutics market landscape? – Identify, understand and capitalize.

1 Table of Contents

1 Table of Contents 3

1.1 List of Tables 5

1.2 List of Figures 6

2 Asthma Therapeutics: Introduction 7

2.1 Disease Overview 7

2.1.1 Epidemiology 7

2.1.2 Classic Signs and Symptoms 9

2.1.3 Etiology 9

2.1.4 Diagnosis 10

2.1.5 Classification 11

2.1.6 Pathogenesis of Asthma 12

2.1.7 Treatment 14

2.1.8 Referral Pathway 16

2.2 GlobalData Pipeline Report Guidance 17

3 Asthma Therapeutics: Market Characterization 18

3.1 Asthma Therapeutics Market Size (2005–2010) – Global 18

3.2 Asthma Therapeutics Market Forecast (2010–2018) – Global 19

3.3 Asthma Therapeutics Market Size (2005–2010) – The US 20

3.4 Asthma Therapeutics Market Forecast (2010–2018) – The US 21

Asthma Therapeutics Market Size (2005–2010) – France 22

3.5 Asthma Therapeutics Market Forecast (2010–2018) – France 23

3.6 Asthma Therapeutics Market Size (2005–2010) – Germany 24

3.7 Asthma Therapeutics Market Forecast (2010–2018) – Germany 25

3.8 Asthma Therapeutics Market Size (2005–2010) – Italy 26

3.9 Asthma Therapeutics Market Forecast (2010–2018) – Italy 27

3.10 Asthma Therapeutics Market Size (2005–2010) – Spain 28

3.11 Asthma Therapeutics Market Forecast (2010–2018) – Spain 29

3.12 Asthma Therapeutics Market Size (2005–2010) – The UK 30

3.13 Asthma Therapeutics Market Forecast (2010–2018) – The UK 31

3.14 Asthma Therapeutics Market Size (2005–2010) – Japan 32

3.15 Asthma Therapeutics Market Forecast (2010–2018) – Japan 33

3.16 Drivers and Barriers for the Asthma Therapeutics Market 34

3.16.1 Drivers for the Asthma Therapeutics Market 34

3.16.2 Barriers for the Asthma Therapeutics Market 34

3.17 Opportunity and Unmet Need Analysis 35

3.18 Key Take away 35

4 Asthma Therapeutics: Competitive Assessment 36

4.1 Overview 36

4.2 Strategic Competitor Assessment 36

4.3 Marketed Product Profiles 37

4.3.1 Advair Diskus (fluticasone propionate and salmeterol inhalation powder) 37

4.3.2 Symbicort (budesonide/formoterol fumarate dihydrate inhalation aerosol) 40

4.3.3 Singulair (montekeulast sodium) 41

4.3.4 Foradil (formoterol fumarate inhalation powder) 43

4.3.5 Accolate (zafirlukast) 46

4.3.6 Xolair (omalizumab) 48

4.3.7 Serevent Diskus (salmaterol xinafoate inhalation powder) 49

4.3.8 Dulera/Zenhale (SCH 418131) 51

5 Asthma Therapeutics: Pipeline Assessment 55

5.1 Overview 55

5.2 Strategic Pipeline Assessment 55

5.3 Asthma Therapeutics Pipeline – Pipeline by Phases of Development 56

5.3.1 Asthma Therapeutics – NDA Filed Products 56

5.3.2 Asthma Therapeutics – Phase III Pipeline 57

5.3.3 Asthma Therapeutics – Phase II Pipeline 58

5.3.4 Asthma Therapeutics – Phase I Pipeline 60

5.3.5 Asthma Therapeutics – Pre-Clinical Pipeline 61

5.3.6 Asthma Therapeutics – Discovery Pipeline 62

5.3.7 Technology Trends Analytic Framework 63

5.4 Asthma Therapeutics –Pipeline by Mechanism of Action 65

5.5 Asthma Therapeutics – Promising Drugs under Clinical Development 66

5.6 Molecule Profile for Promising Drugs under Clinical Development 67

5.6.1 Relovair 67

5.6.2 CHF 1535 100/6 NEXT DPI or CHF 1535 pMDI 68

5.6.3 Flutiform (fluticasone proprionate and formoterol fumarate inhalation aerosol) 69

5.6.4 Reslizumab 69

5.6.5 VR315 70

5.6.6 Andolast (CR 2039): 71

5.6.7 KCA-757/MN-001 71

5.6.8 Budesonide-Formoterol Formulation 72

5.6.9 Fluticasone-Salmeterol Formulation 73

5.7 Key Takeaway 73

6 Asthma Therapeutics: Clinical Trials Mapping 74

6.1 Clinical Trials by Region/Country (US, EU5 and Japan) 74

6.2 Clinical Trials by Phase 75

6.3 Clinical Trials by Trial Status 76

6.4 Prominent Sponsors 77

6.5 Top Companies Participating in Asthma Therapeutics Clinical Trials 79

7 Strategic Assessment 80

7.1 Key Events Impacting the Future Market 80

7.2 Asthma Therapeutics: Implications for Future Market Competition 81

8 Asthma Therapeutics: Future Players 82

8.1 Introduction 82

8.2 Company Profiles 83

8.2.1 GlaxoSmithKline Plc. 83

8.2.2 Merck & Co., Inc. 86

8.2.3 Novartis AG 88

8.2.4 AstraZeneca 90

8.2.5 Cephalon, Inc. 92

8.2.6 Vectura 94

8.2.7 Orion Corporation 95

8.2.8 Rottapharma SPA 97

8.2.9 SkyePharma PLC 98

9 Asthma Therapeutics: Licensing and Partnership Deals 100

10 Asthma Therapeutics: Appendix 105

10.1 Market Definitions 105

10.2 Abbreviations 105

10.3 Methodology 106

10.3.1 Coverage 106

10.3.2 Secondary Research 107

10.3.3 Forecasting 107

10.3.4 Primary Research 109

10.3.5 Expert Panel Validation 110

10.4 Contact Us 110

10.5 Disclaimer 110

10.6 Bibliography 110

List of Tables

Table 1: Asthma Therapeutics Market, Global, Revenue ($bn), 2005–2010 18

Table 2: Asthma Therapeutics Market, Global, Forecast ($bn), 2010–2018 19

Table 3: Asthma Therapeutics Market, The US, Revenue ($bn), 2005–2010 20

Table 4: Asthma Therapeutics Market, The US, Forecast ($bn), 2010–2018 21

Table 5: Asthma Therapeutics Market, France, Revenue ($m), 2005–2010 22

Table 6: Asthma Therapeutics Market, France, Forecast ($m), 2010–2018 23

Table 7: Asthma Therapeutics Market, Germany, Forecast ($m), 2005–2010 24

Table 8: Asthma Therapeutics Market, Germany, Forecasts ($m), 2010–2018 25

Table 9: Asthma Therapeutics Market, Italy, Revenue ($m), 2005–2010 26

Table 10: Asthma Therapeutics Market, Italy, Forecast ($m), 2010–2018 27

Table 11: Asthma Therapeutics Market, Spain, Revenue ($m), 2005–2010 28

Table 12: Asthma Therapeutics Market, Spain, Forecast ($m), 2010–2018 29

Table 13: Asthma Therapeutics Market, The UK, Revenue ($m), 2005–2010 30

Table 14: Asthma Therapeutics Market, The UK, Forecast ($m), 2010–2018 31

Table 15: Asthma Therapeutics Market, Japan, Revenue ($m), 2005–2010 32

Table 16: Asthma Therapeutics Market, Japan, Forecast ($bn), 2010–2018 33

Table 17: Adverse Reactions With 3% Incidence With Advair Diskus in Adult and Adolescent Patients With Asthma. 38

Table 18: Pooled Data From Three 12-Week, Double-Blind, Placebo-Controlled Clinical Asthma Trials In Patients 12 Years And Older 40

Table 19: Adverse Experiences Occurring in 1% of Patients with an Incidence Greater than that in Patients Treated with Placebo 42

Table 20: Effect of Singulair on Primary and Secondary Endpoints in a Multinational Placebo-Controlled Trial 43

Table 21: Number And Frequency Of Adverse Experiences In Patients From Multiple-Dose Controlled Clinical Trials 44

Table 22: Efficacy Results of Study 40 of Foradil 45

Table 23: Symptom and Rescue Medication Use (Adults with Asthma) 45

Table 24: A Comparison of Adverse Events Reported by 1% of Zafirlukast-Treated Patients 47

Table 25: Mean Change from Baseline at Study End Point 47

Table 26: Adverse Reaction Incidence in Two 12-Week Clinical Trials in Adult and Adolescent Patients With Asthma 50

Table 27: Study Design of Phase III trial 53

Table 28: Clinical Trial with Dulera 100 mcg/5 mcg Clinically Judged Deterioration in Asthma or Reduction In Lung Function 53

Table 29: Clinical Trial With Dulera 200 mcg/5 mcg Clinically Judged Deterioration in Asthma or Reduction in Lung Function 54

Table 30: Asthma Therapeutics, NDA Filed Products, 2011 56

Table 31: Asthma Therapeutics, Phase III Pipeline, 2011 57

Table 32: Asthma Therapeutics, Phase II Pipeline, 2011 58

Table 33: Asthma Therapeutics, Phase I Pipeline, 2011 60

Table 34: Asthma Therapeutics, Pre-Clinical Pipeline, 2011 61

Table 35: Asthma Therapeutics, Discovery Pipeline, 2011 62

Table 36: Asthma Therapeutics – Most Promising Drugs Under Clinical Development, 2011 66

Table 37:Study Details of CHF 1535 100/6 NEXT DPI 69

Table 38: Asthma Therapeutics, Clinical Trials by Country, 2011 74

Table 39: Asthma Therapeutics – Clinical Trials by Phase, 2011 75

Table 40: Asthma Therapeutics, Clinical Trials by Status , 2011 76

Table 41: Asthma Therapeutics, Prominent Sponsors, 2011 78

Table 42: Asthma Therapeutics, Top Companies Participating in Therapeutics Clinical Trials, 2011 79

Table 43: GSK – Respiratory and Immuno-inflamation Pipeline Products, 2011 85

Table 44: GSK –Asthma Pipeline Products, 2011 85

Table 45: Merck & Co., Inc. – Respiratory Pipeline, 2011 87

Table 46: Merck & Co., Inc. – Asthma pipeline, 2011 88

Table 47: Novartis AG – Respiratory pipeline 89

Table 48: Novartis AG – Asthma Pipeline 89

Table 49: AstraZeneca – Respiratory Pipeline Products, 2011 91

Table 50: AstraZeneca – Asthma Pipeline Products, 2011 91

Table 51: Orion Corporation – Respiratory Pipeline, 2011 96

Table 52: Orion Corporation – Respiratory Pipeline, 2011 97

Table 53: Asthma Therapeutics, Global, Deals, 2009-2011 100

List of Figures

Figure 1: Asthma Prevalence Control Extrapolated to The European Union Population (in millions) 8

Figure 2: Asthma Etiology Hypothesis With Common Triggers 10

Figure 3: Classification of Asthma Control 11

Figure 4: T lymphocytes in Allergic Asthma 12

Figure 5: Phases of Asthmatic Attack. 13

Figure 6: Treatment Of Chronic asthma 15

Figure 7: Asthma Referral Pathway 16

Figure 8: Asthma Therapeutics Market, Global, Revenue ($bn), 2005–2010 18

Figure 9: Asthma Therapeutics Market, Global, Forecast ($bn), 2010–2018 19

Figure 10: Asthma Therapeutics Market, The US, Revenue ($bn), 2005–2010 20

Figure 11: Asthma Therapeutics Market, The US, Forecast ($bn), 2010–2018 21

Figure 12: Asthma Therapeutics Market, France, Revenue ($m), 2005–2010 22

Figure 13: Asthma Therapeutics Market, France, Forecast ($m), 2010–2018 23

Figure 14: Asthma Therapeutics Market, Germany, Revenue ($m), 2005–2010 24

Figure 15: Asthma Therapeutics Market, Germany, Forecast ($m), 2010–2018 25

Figure 16: Asthma Therapeutics Market, Italy, Revenue ($m), 2005–2010 26

Figure 17: Asthma Therapeutics Market, Italy, Forecast ($m), 2010–2018 27

Figure 18: Asthma Therapeutics Market, Spain, Revenue ($m), 2005–2010 28

Figure 19: Asthma Therapeutics Market, Spain, Forecast ($m), 2010–2018 29

Figure 20: Asthma Therapeutics Market, The UK, Revenue ($m), 2005–2010 30

Figure 21: Asthma Therapeutics Market, The UK, Forecast ($m), 2010–2018 31

Figure 22: Asthma Therapeutics Market, Japan, Revenue ($m), 2005–2010 32

Figure 23: Asthma Therapeutics Market, Japan, Forecast ($m), 2010–2018 33

Figure 24: Opportunity and Unmet Need in the Asthma Therapeutics Market, 2010 35

Figure 25: Asthma Therapeutics, Strategic Competitor Assessment, 2010 36

Figure 26: Asthma Therapeutics, Molecular Structure of Zenhale 52

Figure 27: Asthma Therapeutics – Pipeline by Phase of Development, 2011 56

Figure 28: Asthma Therapeutics, Technology Trends Analytics Framework, 2011 63

Figure 29: Asthma Therapeutics, Technology Trends Analytics Framework, Description, 2011 64

Figure 30: Asthma Therapeutics, Pipeline by Mechanism of Action (%), 2011 65

Figure 31: Asthma Therapeutics, Molecular Structure of Relovair 67

Figure 32: Asthma Therapeutics, Molecular Structure of Foster 68

Figure 33: Structure of Andolast 71

Figure 34: KCA 757/MN001 Structure 72

Figure 35: Asthma Therapeutics, Clinical Trials by Country, 2011 74

Figure 36: Asthma Therapeutics, Clinical Trials by Phase (%), 2011 75

Figure 37: Asthma Therapeutics, Clinical Trials by Status (%), 2011 76

Figure 38: Asthma Therapeutics, Overall Sponsors (%), 2011 77

Figure 39: Asthma Therapeutics, Prominent Sponsors (%), 2011 78

Figure 40: Asthma Therapeutics, Top Companies Participating in Clinical Trials, 2011 79

Figure 41: Asthma Therapeutics Market, Drivers and Restraints, 2011 80

Figure 42: Implications for Future Market Competition in the Asthma Market, 2011 81

Figure 43: Asthma Therapeutics Market, Pipeline by Company, 2011 82

Figure 44: GlobalData Market Forecasting Model 109

Companies Mentioned

GlaxoSmithKline Plc.

Merck & Co., Inc.

Novartis AG

AstraZeneca

Cephalon, Inc.

Vectura

Orion Corporation

Rottapharma SPA

SkyePharma PLC

To order this report:

Pathology Industry: Asthma Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Pathology Business News

More  Market Research Report

Check our  Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

Back to top

RELATED LINKS
http://www.reportlinker.com